To recover your password please fill in your email address
Please fill in below form to create an account with us
A phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant ovarian cancer
|
Trial Summary: |
This study will evaluate the activity of intraperitoneal bevacizumab in delaying reaccumulation of ascites in patients with chemotherapy resistant ovarian, peritoneal and fallopian tube cancers and symptomatic ascites. |
|
Supported By: |
Cancer Australia and Ovarian Cancer Research Foundation and Chairs: Katrin Sjoquist and Michael Friedlander |
|
Eligibility: |
Women with a chemotherapy resistant ovarian, peritoneal or fallopian tube cancer and symptomatic ascites that has recurred within 4 weeks or therapeutic drainage and who are no longer receiving chemotherapy. |
|
Registration ID: |
ACTRN12611000801910 |
|
Participation: |
Australia |
|
Australian Lead Group: |
ANZGOG |
|
Status: |
Closed |
|
Activation Date: |
1/11/2013 |
|
Chairs: |
Katrin Sjoquist and Michael Friedlander |
|
Contact: |